ATE237346T1 - Gebrauch von galanin um nervenschäden zu reparieren - Google Patents

Gebrauch von galanin um nervenschäden zu reparieren

Info

Publication number
ATE237346T1
ATE237346T1 AT97932939T AT97932939T ATE237346T1 AT E237346 T1 ATE237346 T1 AT E237346T1 AT 97932939 T AT97932939 T AT 97932939T AT 97932939 T AT97932939 T AT 97932939T AT E237346 T1 ATE237346 T1 AT E237346T1
Authority
AT
Austria
Prior art keywords
galanin
treatment
nerve damage
supression
pain
Prior art date
Application number
AT97932939T
Other languages
English (en)
Inventor
David Wynick
Original Assignee
Neurotargets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615551.0A external-priority patent/GB9615551D0/en
Priority claimed from GBGB9623869.6A external-priority patent/GB9623869D0/en
Application filed by Neurotargets Ltd filed Critical Neurotargets Ltd
Application granted granted Critical
Publication of ATE237346T1 publication Critical patent/ATE237346T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT97932939T 1996-07-24 1997-07-24 Gebrauch von galanin um nervenschäden zu reparieren ATE237346T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9615551.0A GB9615551D0 (en) 1996-07-24 1996-07-24 Galanin
GBGB9623869.6A GB9623869D0 (en) 1996-11-15 1996-11-15 Galanin
PCT/GB1997/001991 WO1998003059A1 (en) 1996-07-24 1997-07-24 Galanin

Publications (1)

Publication Number Publication Date
ATE237346T1 true ATE237346T1 (de) 2003-05-15

Family

ID=26309752

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97932939T ATE237346T1 (de) 1996-07-24 1997-07-24 Gebrauch von galanin um nervenschäden zu reparieren
AT02028584T ATE457125T1 (de) 1996-07-24 1997-07-24 Verwendung eines galanin-agonisten in der herstellung eines medikaments zur verbesserung des gedächtnisses und anderer cognitiver funktionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02028584T ATE457125T1 (de) 1996-07-24 1997-07-24 Verwendung eines galanin-agonisten in der herstellung eines medikaments zur verbesserung des gedächtnisses und anderer cognitiver funktionen

Country Status (11)

Country Link
US (1) US20030009777A1 (de)
EP (2) EP1342410B1 (de)
JP (1) JP2000516212A (de)
AT (2) ATE237346T1 (de)
AU (1) AU3630297A (de)
DE (2) DE69739760D1 (de)
DK (2) DK1342410T3 (de)
ES (2) ES2340984T3 (de)
GB (1) GB2331301C (de)
PT (2) PT918455E (de)
WO (1) WO1998003059A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU730137B2 (en) 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
JP2005507654A (ja) * 2001-08-27 2005-03-24 トゥラリック インコーポレイテッド 増幅した癌遺伝子およびそれらの癌への関与
AU2003211562A1 (en) * 2002-02-22 2003-09-09 Takeda Chemical Industries, Ltd. Novel dna and use thereof
GB0403509D0 (en) * 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
JP2008517930A (ja) * 2004-10-21 2008-05-29 トランス テック ファーマ,インコーポレイテッド GalR1のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
WO2008086573A1 (en) * 2007-01-19 2008-07-24 Howard Florey Institute Of Experimental Physiology And Medicine Use of galanin in a method of treating neurodegenerative diseases or conditions
WO2009043478A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100204129A1 (en) * 2008-09-09 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
ES2883838A1 (es) * 2020-06-04 2021-12-09 Univ Malaga Prevencion y/o tratamiento del deterioro cognitivo asociado a sindromes de demencia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012997A1 (en) * 1991-01-16 1992-08-06 The General Hospital Corporation Human galanin
WO1992015015A1 (en) * 1991-02-25 1992-09-03 Zymogenetic, Inc. Methods for detecting galanin antagonists
CA2105572A1 (en) * 1991-03-06 1992-09-07 Helen F. Evans Human galanin, cdna clones encoding human galanin and a method of producing human galanin
SE9101472D0 (sv) 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
JPH06172387A (ja) * 1992-12-11 1994-06-21 Aibaitsu Kk 合成ペプチド誘導体
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
AU730137B2 (en) * 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof

Also Published As

Publication number Publication date
DK1342410T3 (da) 2010-05-31
ES2196349T3 (es) 2003-12-16
GB2331301C (en) 2005-05-22
WO1998003059A1 (en) 1998-01-29
DE69739760D1 (de) 2010-03-25
PT918455E (pt) 2003-09-30
ATE457125T1 (de) 2010-02-15
PT1342410E (pt) 2010-05-11
EP0918455B1 (de) 2003-04-16
DK0918455T3 (da) 2003-08-04
AU3630297A (en) 1998-02-10
EP1342410A2 (de) 2003-09-10
EP1342410B1 (de) 2010-02-10
DE69721005T2 (de) 2004-06-09
DE69721005D1 (de) 2003-05-22
ES2340984T3 (es) 2010-06-14
EP1342410A3 (de) 2003-12-10
GB2331301B (en) 2001-02-14
GB9901264D0 (en) 1999-03-10
GB2331301A (en) 1999-05-19
EP0918455A1 (de) 1999-06-02
US20030009777A1 (en) 2003-01-09
JP2000516212A (ja) 2000-12-05

Similar Documents

Publication Publication Date Title
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE60035057D1 (de) CD40 Antagonist zur Behandlung von Psoriasis
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
IL225191A0 (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
YU13301A (sh) Muskarinski agonisti i antagonisti
DE69721005D1 (de) Gebrauch von galanin um nervenschäden zu reparieren
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
ATE258791T1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE326265T1 (de) Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
PT1152757E (pt) Inibidores de mmp no amolecimento do tecido conjuntivo
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE333287T1 (de) Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten
ATE345138T1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0918455

Country of ref document: EP

REN Ceased due to non-payment of the annual fee